#United States #New York #Pomerantz #Ultragenyx #RARE

Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc.

On January 22, 2026, the Pomerantz Law Firm announced that it is conducting an investigation on behalf of investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This initiative stems from serious allegations suggesting that the company, along with certain executives and board members, may have been involved in securities fraud or engaged in other unethical business operations. The investigation is focused on the company’s reported outcomes from recent clinical trials, which have raised significant concerns among investors.

In the early hours of December 29, 2025, prior to the market opening, Ultragenyx revealed the outcomes of two critical Phase 3 clinical trials concerning setrusumab, a treatment aimed at addressing bone metabolism disorders. Unfortunately, neither of these studies was able to demonstrate statistical significance for their primary endpoints, which aimed at reducing the annualized clinical fracture rate when compared to placebo or bisphosphonates. However, both studies successfully reached their secondary endpoints, which involved significant increases in bone mineral density over the comparators. Importantly, there were no changes reported regarding the safety profiles related to the drug.

The announcement of these results had a drastic impact on Ultragenyx's stock price, causing it to plummet by $2.02 per share, equivalent to a staggering 87.64% decline, concluding the trading session at just $0.28 per share. This decline has alarmed investors, prompting the firm to investigate potential legal action.

Pomerantz LLP, established by the prominent figure Abraham L. Pomerantz, has a revered reputation as one of the leading law firms specializing in corporate, securities, and antitrust class litigation. With notable offices across New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, it has dedicated itself for over eight decades to advocate for the rights of investors who have suffered from securities fraud and corporate misconduct. Over its esteemed history, the firm has garnered several significant damage awards for victims of corporate transgressions, emphasizing its commitment to justice.

Potentially affected investors of Ultragenyx are encouraged to reach out to Danielle Peyton at Pomerantz LLP for more information about joining a class action lawsuit. Interested parties can contact her via email at [email protected] or by phone at 646-581-9980, ext. 7980.

The continuing developments surrounding Ultragenyx's performance and the ongoing investigation by Pomerantz Law Firm underline the necessity for vigilance within the investing community, especially in the biotech sector, where clinical results can significantly influence stock performance and investor confidence.